Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma (Q36832132)

16 August 2017

1 reference

title

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma (English)

1 reference

16 August 2017

1 reference

T A Waldmann

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

25

1 reference

16 August 2017

page(s)

3699-3703

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210368

16 August 2017

exact match

0 references

cites work

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Molecular cloning and expression of cDNAs for the human interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Advances in interleukin 2 receptor targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

A humanized antibody that binds to the interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The soluble interleukin-2 receptor: biology, function, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The multi-subunit interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The meandering 45-year odyssey of a clinical immunologist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210368

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210368

1 reference

16 August 2017

1 reference